Midwest Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Midwest Trust’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$414K	Buy	791 +170	+27%	+$87K	﹤0.01%	492
2026 Q2	$308K	Buy	621 +23	+4%	+$10.2K	﹤0.01%	526
2026 Q1	$267K	Buy	598 +2	+0.3%	+$933	﹤0.01%	530
2025 Q4	$270K	Sell	596 -24	-4%	-$10.3K	﹤0.01%	530
2025 Q3	$243K	Buy	620 +49	+9%	+$20.5K	﹤0.01%	548
2025 Q2	$254K	Buy	+571	New	+$263K	﹤0.01%	547

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return

Midwest Trust's VRTX Position: Q3 2026 in Review

Midwest Trust increased its Vertex Pharmaceuticals (VRTX) stake by 27% in Q3 2026, buying an estimated $87K and bringing the position to 791 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #492.

Midwest Trust first reported a position in VRTX in Q2 2025 and has held it in 6 quarters since. 478 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Midwest Trust held 791 shares of Vertex Pharmaceuticals worth $414K as of Q3 2026.
Midwest Trust bought 170 Vertex Pharmaceuticals shares in Q3 2026, an estimated $87K.
Vertex Pharmaceuticals made up ﹤0.01% of Midwest Trust's portfolio in Q3 2026, its #492 holding.
Midwest Trust first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
478 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Midwest Trust's 13F filing for Q3 2026, filed 22 Oct 2026.